Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01038622
Other study ID # P090203
Secondary ID
Status Completed
Phase Phase 4
First received December 22, 2009
Last updated September 17, 2013
Start date November 2009
Est. completion date January 2011

Study information

Verified date December 2009
Source Assistance Publique - Hôpitaux de Paris
Contact n/a
Is FDA regulated No
Health authority France: Ministry of Health
Study type Interventional

Clinical Trial Summary

The main objective of this proof-of-concept study is to demonstrate that the only administration of L-arginine, based on a suspected deficit monitored by nasal nitric oxide measurement, can improve immune functions in critically ill patients at high risk of nosocomial infection.


Description:

Background : A meta-analysis has demonstrated the beneficial effect of immuno nutrition in surgical patients, leading to half reduction of incidence of nosocomial infections (HEYLAND DK, JAMA ; 2001). This beneficial effect seems to be related to L-arginine content of formula. In medical intensive care, such an improvement has not been shown, in spite of similar impairment of immune response, which could be due to a more heterogenous population. Our hypothesis is that this beneficial effect could be observed in selected patients of medical intensive care units. L-arginine is a semi-essential amino acid that is the precursor of nitric oxide (NO) synthesis. NO is involved in immune response regulation and has antimicrobial properties, notably into airways where it can be measured in exhaled gas. A decrease in exhaled and nasal NO has been demonstrated in critically ill patients, which may suggest an impairment of its production.

Objectives : The aim of this study is to evaluate the immune effects of enteral L-arginine administration in non surgical critically ill patients. These patients will be selected based on the decrease in nasal NO: directed immuno nutrition. The main objective is to demonstrate that L-arginine administration, as compared to placebo administration, increases nasal NO and enhances immune functions (increase in HLA-DR expression on monocytes, modification of circulating Myeloid-Derived Suppressor Cells (MDSC), decrease in IL-6, IL-17 plasmatic concentrations): stimulation of immune response. The secondary objective is to demonstrate the safety of L-arginine administration on organ failure and on the incidence of nosocomial infections.

This is a monocentric therapeutic trial, randomized and double blind: standard enteral nutrition plus L-arginine (200 mg/kg/d for 5 days from the admission in ICU) versus standard enteral nutrition plus placebo.

Methods-Patients: Non surgical patients admitted in a single medical intensive care unit, under mechanical ventilation for an expected duration > 2 days, with decreased concentrations of nasal NO (< 60 ppb), without severe sepsis or septic shock, will be enrolled. On admission (before treatment), the severity will be evaluated (SAPS II and SOFA score) together with an assessment of plasmatic L-arginine, cytokines (IL-6, IL-17), MDSC, and expression of HLA-DR by monocytes. The same evaluation will be repeated on day 4 (during treatment) and on day 7 (after treatment). The enrolment of 50 patients is statistically enough to demonstrate an increased expression of HLA-DR in the L-arginine group as compared to the placebo group on day 4.

Expected results and perspectives: The aim of this study is to demonstrate the validity of the concept of directed immune stimulation by the sole L-arginine in medical intensive care unit, the patients being selected based on their decrease in exhaled and nasal NO concentrations. This pathophysiological study is the necessary first step before conducting a large clinical trial aimed at demonstrating a reduction of nosocomial infection incidence by L-arginine.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date January 2011
Est. primary completion date November 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion criteria :

- age > 18 years

- medical patient (absence of recent surgery or trauma)

- initial aggression < 5 days

- mechanically ventilated with expected duration of mechanical ventilation > 2 days

- enteral nutrition

- absence of previous immunosuppression

- nasal NO on day 1 of ICU stay < 60 ppb

Exclusion criteria :

- severe sepsis

- septic shock

- condition associated with a decreased nasal NO concentration (cystic fibrosis, nasal polyposis, primary ciliary dyskinesia

- pregnancy

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
L-arginine
5-day L-arginine treatment
placebo
5-day placebo treatment

Locations

Country Name City State
France Medical Intensive Care Unit, Pompidou Hospital Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

References & Publications (1)

Marik PE, Zaloga GP. Immunonutrition in critically ill patients: a systematic review and analysis of the literature. Intensive Care Med. 2008 Nov;34(11):1980-90. doi: 10.1007/s00134-008-1213-6. Epub 2008 Jul 15. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Expression of HLA-DR in the L-arginine group as compared to the placebo group on day 3 No
Secondary HLA-DR on day 7, IL-10 and IL-17 on day 3 and 7, MDSC on day 3 and 7 on day 3 and on day 7 No
Secondary Nosocomial infections in the first 15 days No
Secondary Safety issue: organ failure score (SOFA score) on day 3 and 7; issue from ICU on day 3 and 7 Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05539521 - Efficacy and Safety of Remimazolam Besylate Versus Propofol for Sedation in Critically Ill Patients With Deep Sedation Phase 2
Recruiting NCT04776486 - Iohexol Clearance in Critically Ill Patients With Augmented Renal Creatinine Clearance N/A
Completed NCT05766319 - The ICU-recover Box, Using Smart Technology for Monitoring Health Status After ICU Admission N/A
Recruiting NCT03231540 - The PREServation of MUScle Function in Critically Ill Patients (PRESMUS) N/A
Completed NCT02286869 - Cardioventilatory Coupling in Critically Ill Patients N/A
Completed NCT01434823 - 24 Hour Intensivist Coverage in the Medical Intensive Care Unit N/A
Active, not recruiting NCT01142570 - Effect of Enteral Nutrition Enriched in Protein and Based on Indirect Calorimetry Measurement in Chronically Critically Ill Patients N/A
Completed NCT01167595 - Enhanced Protein-Energy Provision Via the Enteral Route in Critically Ill Patients N/A
Not yet recruiting NCT00916591 - Prokinetic Drugs and Enteral Nutrition N/A
Completed NCT01293708 - Realities, Expectations and Attitudes to Life Support Technologies in Intensive Care for Octogenarians:
Recruiting NCT00654797 - Improving Blood Glucose Control With a Computerized Decision Support Tool: Phase 2 Phase 2
Withdrawn NCT00178321 - Improving Sleep in the Pediatric Intensive Care Unit N/A
Completed NCT01168128 - PERFormance Enhancement of the Canadian Nutrition Guidelines by a Tailored Implementation Strategy: The PERFECTIS Study N/A
Completed NCT02447692 - Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The PROMIZING Study N/A
Recruiting NCT04582760 - Early Mobilization in Ventilated sEpsis & Acute Respiratory Failure Study N/A
Not yet recruiting NCT05961631 - Bio-electrical Impedance Analysis Derived Parameters for Evaluating Fluid Accumulation
Completed NCT03276650 - Admission of Adult-onset Still Disease Patients in the ICU
Completed NCT03922113 - Muscle Function After Intensive Care
Recruiting NCT05055830 - Opportunistic PK/PD Trial in Critically Ill Children (OPTIC)
Recruiting NCT06027008 - Mechanical Insufflation-Exsufflation (Cough Assist) in Critically Ill Adults N/A